Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2004 May;113(10):1387-9.
doi: 10.1172/JCI21819.

Sepsis: avoiding its deadly toll

Affiliations
Comment

Sepsis: avoiding its deadly toll

Thomas Decker. J Clin Invest. 2004 May.

Abstract

Systemic bacterial infection may culminate in a frequently fatal septic shock syndrome. The underlying pathology is the result of an uncontrolled inflammatory response, stimulated by the pathogen and its products. Toll-like receptors (TLRs) are critically involved in sensing bacteria and, in the case of sepsis, stimulate a pathogenic response by the innate immune system. A new study reports a successful attempt to inhibit systemic inflammation in mice by disrupting the formation of complexes between Gram-positive bacteria and their cognate receptor, TLR2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential targets of treatments of septic shock. Interaction of bacteria with receptors recognizing PAMPs like the TLRs stimulates cells of the innate immune system to produce proinflammatory molecules, which, together with components of the activated complement and coagulation systems, promote the development of septic shock syndrome. Some prominent examples of molecules involved in the inflammatory cascade are shown in parentheses.

Comment on

References

    1. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J. Clin. Invest. 2003;112:460–467. doi:10.1172/JCI200319523. - PMC - PubMed
    1. Angus DC, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001;29:1303–1310. - PubMed
    1. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat. Med. 2003;9:517–524. - PubMed
    1. Meng G, et al. Antagonistic antibody prevents toll-like receptor 2–driven lethal shock-like syndromes. J. Clin. Invest. 2004;113:1473–1481. doi:10.1172/JCI200420762. - PMC - PubMed
    1. Medzhitov R, Janeway CA., Jr Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997;91:295–298. - PubMed

Publication types